Tvardi Therapeutics
TVRD
122 hedge funds and large institutions have $45.6M invested in Tvardi Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 30 closing their positions.
169% more call options, than puts
Call options by funds: $132K | Put options by funds: $49K
0.12% less ownership
Funds ownership: 1.51% → 1.39% (-0.12%)
10% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 39
11% less funds holding
Funds holding: 137 → 122 (-15)
45% less capital invested
Capital invested by funds: $83.3M → $45.6M (-$37.7M)
47% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$1.99M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.69M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.1M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$677K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$655K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$2.37M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.79M |
| 3 |
E
Ergoteles
New York
|
-$1.01M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$958K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$597K |
TVRD Hedge Fund Activity: Q3 2023 in Review
122 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2023, worth a combined $45.6M — down 45% from $83.3M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TVRD and 16 opened new positions — a net loss of 14 holders — while 39 trimmed existing stakes and 35 added.
The largest buyer was IQ EQ Fund Management, adding an estimated $1.99M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $2.37M.
- 122 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2023, down from 137 in Q2 2023.
- Funds reported $45.6M of Tvardi Therapeutics stock for Q3 2023, down 45% quarter-over-quarter.
- 16 funds opened new Tvardi Therapeutics positions in Q3 2023 and 30 closed out, a net change of -14 holders.
- The largest Tvardi Therapeutics buyer in Q3 2023 was IQ EQ Fund Management, an estimated $1.99M added.
- The largest Tvardi Therapeutics seller in Q3 2023 was Bain Capital Life Sciences Investors, an estimated $2.37M sold.
Based on aggregated 13F filings for Q3 2023.